A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002106|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Ranitidine hydrochloride||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||104 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3|
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients must have:
- Asymptomatic HIV-1 infection.
- CD4 count of 400-700 cells/mm3.
Patients with the following symptoms or conditions are excluded:
- Significant illness.
- Acute illness at randomization.
- Antiretroviral use within 60 days prior to study entry.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002106
|United States, California|
|Pacific Oaks Med Group|
|Sherman Oaks, California, United States, 91403|
|United States, Florida|
|Community Research Initiative|
|Coral Gables, Florida, United States, 33146|
|United States, North Carolina|
|Duke Univ Med Ctr|
|Durham, North Carolina, United States, 27710|
|United States, Texas|
|Houston Clinical Research Network|
|Houston, Texas, United States, 77006|
|Other Study ID Numbers:||
|First Posted:||August 31, 2001 Key Record Dates|
|Last Update Posted:||June 24, 2005|
|Last Verified:||May 1994|
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
RNA Virus Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Ranitidine bismuth citrate
Histamine H2 Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs